CTI BioPharma Plans Q4 Pacritinib NDA, Accelerated OK
This article was originally published in Scrip
Executive Summary
Shares of CTI BioPharma rose nearly 12% on Sept. 23 after the company said it plans to submit a new drug application (NDA) in the fourth-quarter for pacritinib following a "productive" meeting with the FDA.